Frazier Life Sciences Management, L.P. Rhythm Pharmaceuticals, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.67 Billion
- Q4 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 1,869,808 shares of RYTM stock, worth $108 Million. This represents 6.27% of its overall portfolio holdings.
Number of Shares
1,869,808
Previous 2,416,952
22.64%
Holding current value
$108 Million
Previous $127 Million
17.45%
% of portfolio
6.27%
Previous 6.82%
Shares
8 transactions
Others Institutions Holding RYTM
# of Institutions
214Shares Held
64.4MCall Options Held
445KPut Options Held
26.6K-
Black Rock Inc. New York, NY6.74MShares$389 Million0.01% of portfolio
-
Primecap Management CO Pasadena, CA6.57MShares$379 Million0.29% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$351 Million5.51% of portfolio
-
Baker Bros. Advisors LP New York, NY6.08MShares$351 Million3.77% of portfolio
-
Perceptive Advisors LLC New York, NY3.68MShares$212 Million6.86% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.21B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...